Interview: Anand Grover of the Lawyers Collective
The Indian Supreme Court’s rejection of Novartis’s Glivec patent brought the increasingly tense debate about the balance between patent rights and access to medicines to the forefront. Anand Grover, who successfully represented the Cancer Patient Aid Association in the case, argues that the patent system may not be the best way to encourage drug research
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
